Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors

Listen to CLL experts Jeff Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from live CCO Webinars on optimizing BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL).

Danielle Brander, MD Nicole Lamanna, MD Jeff Sharman, MD Released: September 17, 2020

Hear from experts Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, as they answer audience questions from the second in a series of live CCO Webinars on optimizing BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL).

Danielle Brander, MD Nicole Lamanna, MD Jeff Sharman, MD Released: September 16, 2020

Hear from experts Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, as they answer audience questions from the third in a series of live CCO Webinars on optimizing BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL).

Danielle Brander, MD Nicole Lamanna, MD Jeff Sharman, MD Released: September 17, 2020

Gain expert insight with this on-demand Webcast on the latest treatment strategies with BTK inhibitors for improving outcomes in patients with CLL.

Danielle Brander, MD Nicole Lamanna, MD Jeff Sharman, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: September 16, 2020 Expired: No longer available for credit

Overview of the BCR Pathway and BTK in Tumor Development (15 minutes)

BTK Inhibitors in Treatment-Naive CLL (26 minutes)

BTK Inhibitors in Relapsed/Refractory CLL (33 minutes)

BTK Inhibitors: Future Directions (11 minutes)

Why testing for TP53, del(17q), and IGHV status critical for treatment selection and outcome optimization. Here’s my take.

Danielle Brander, MD Released: September 22, 2020

The implications of minimal residual disease status on treatment of CLL is evolving. Here’s my take on what you should know now.

Danielle Brander, MD Released: September 29, 2020

Get the latest information on how investigational noncovalent BTK inhibitors, such as LOXO-305 and ARQ 531, may help treat patients with CLL and resistance to currently available BTK inhibitors.

Jeff Sharman, MD Released: September 25, 2020

Download this short slideset of key takeaways from a live CCO Webinar focused on the optimal use of BTK inhibitors in patients with CLL.

Danielle Brander, MD Nicole Lamanna, MD Jeff Sharman, MD Released: July 10, 2020

Downloadable slides with expert analysis of the BCR pathway and BTK inhibitors in CLL.

Jeff Sharman, MD Released: June 10, 2020

Downloadable slides with expert analysis of potential future applications for BTK inhibitors.

Jeff Sharman, MD Released: June 10, 2020

Downloadable slides with expert analysis of the use of BTK inhibitors for patients with treatment-naive CLL.

Danielle Brander, MD Released: June 10, 2020

Downloadable slides with expert analysis of the optimal use of BTK inhibitors in patients with relapsed/refractory CLL.

Nicole Lamanna, MD Released: June 10, 2020